Dementia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Dementia - Pipeline Review, H2 2016

Dementia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Dementia - Pipeline Review, H2 2016
Published Aug 10, 2016
233 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Dementia - Pipeline Review, H2 2016, provides an overview of the Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dementia
- The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects
- The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dementia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dementia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying

  
Source:
Document ID
GMDHC8345IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents213
  List of Tables122
  List of Figures141
Introduction151
  Global Markets Direct Report Coverage151
Dementia Overview161
Therapeutics Development172
  Pipeline Products for Dementia Overview171
  Pipeline Products for Dementia Comparative Analysis181
Dementia Therapeutics under Development by Companies193
Dementia Therapeutics under Investigation by Universities/Institutes221
Dementia Pipeline Products Glance234
  Late Stage Products231
  Clinical Stage Products241
  Early Stage Products251
  Unknown Stage Products261
Dementia Products under Development by Companies274
Dementia Products under Investigation by Universities/Institutes311
Dementia Companies Involved in Therapeutics Development3247
  Adamas Pharmaceuticals, Inc.321
  AgeneBio Inc.331
  Alector LLC341
  AlzProtect SAS351
  Amarantus Bioscience Holdings, Inc.361
  Anavex Life Sciences Corp.371
  Axon Neuroscience SE381
  Axovant Sciences Ltd.391
  BioArctic Neuroscience AB401
  Biogen Inc411
  Biotie Therapies Corp.421
  Boehringer Ingelheim GmbH431
  Chase Pharmaceuticals Corporation441
  Cortice Biosciences, Inc.451
  Daewoong Pharmaceutical Co., Ltd.461
  Eisai Co., Ltd.471
  Eli Lilly and Company481
  FORUM Pharmaceuticals Inc.491
  H. Lundbeck A/S501
  Heptares Therapeutics Limited511
  Hyundai Pharmaceutical Co., Ltd.521
  Ildong Pharmaceutical Co., Ltd.531
  Immungenetics AG541
  ImStar Therapeutics Inc.551
  Integrative Research Laboratories Sweden AB561
  Intellect Neurosciences, Inc.571
  Intra-Cellular Therapies, Inc.581
  INVENT Pharmaceuticals, Inc.591
  M3 Biotechnology, Inc.601
  MediPost Co., Ltd.611
  Neuraltus Pharmaceuticals, Inc.621
  Neurimmune Holding AG631
  Neurodyn Inc.641
  Oryzon Genomics SA651
  Otsuka Holdings Co., Ltd.661
  P2D Bioscience671
  Pacific Northwest Biotechnology, LLC681
  Pivot Pharmaceuticals Inc691
  Sinil Pharmaceutical Co., Ltd701
  Stelic Institute &Co., Inc.711
  Sumitomo Dainippon Pharma Co., Ltd.721
  Sylentis S.A.U.731
  Takeda Pharmaceutical Company Limited741
  TauRx Therapeutics Ltd.751
  Voyager Therapeutics, Inc.761
  WhanIn Pharmaceutical Co., Ltd.771
  Zhejiang Hisun Pharmaceutical Co., Ltd.781
Dementia Therapeutics Assessment7912
  Assessment by Monotherapy Products791
  Assessment by Combination Products801
  Assessment by Target813
  Assessment by Mechanism of Action843
  Assessment by Route of Administration872
  Assessment by Molecule Type892
Drug Profiles91121
  (donepezil hydrochloride + memantine hydrochloride ER) Drug Profile912
  (donepezil hydrochloride + solifenacin succinate) Drug Profile931
  AADvac-1 Drug Profile941
  AD-35 Drug Profile951
  ANAVEX-371 Drug Profile962
  Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia Drug Profile981
  ASN-561 Drug Profile991
  AVP-786 Drug Profile1003
  AZP-2006 Drug Profile1032
  BAN-0805 Drug Profile1051
  BI-409306 Drug Profile1062
  CB-2233 Drug Profile1081
  CB-8411 Drug Profile1091
  choline alfoscerate SR Drug Profile1101
  D-217 Drug Profile1111
  dehydroevodiamine hydrochloride Drug Profile1121
  Drugs for Dementia Drug Profile1131
  Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia Drug Profile1141
  Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment Drug Profile1151
  DWJ-1365 Drug Profile1161
  E-2609 Drug Profile1172
  eltoprazine Drug Profile1195
  encenicline hydrochloride Drug Profile1245
  FRM-0334 Drug Profile1292
  GIBH-130 Drug Profile1311
  Gln-1062 Drug Profile1323
  GTC-6000 Drug Profile1351
  gugulipid Drug Profile1361
  HOB-075 Drug Profile1371
  HTL-18318 Drug Profile1381
  intepirdine Drug Profile1392
  INV-331 Drug Profile1411
  IRL-752 Drug Profile1421
  ITI-007 Drug Profile1438
  levetiracetam Drug Profile1512
  LUAF-20513 Drug Profile1531
  MM-201 Drug Profile1541
  Monoclonal Antibodies for Alzheimer s Disease and Vascular Dementia Drug Profile1551
  Monoclonal Antibodies for Dementia and Alzheimer's Disease Drug Profile1561
  Monoclonal Antibodies to Inhibit Tau for CNS Disorders Drug Profile1571
  monosodium luminol Drug Profile1582
  NAT Drug Profile1601
  nelotanserin Drug Profile1612
  Neurostem Drug Profile1632
  NI-205 Drug Profile1651
  NI-308 Drug Profile1661
  NNC-269100 Drug Profile1671
  NP-001 Drug Profile1683
  ORY-2001 Drug Profile1712
  P-003 Drug Profile1731
  PD-2015 Drug Profile1741
  PD-2016 Drug Profile1751
  PD-2024 Drug Profile1761
  PD-2244 Drug Profile1771
  Peptide to Inhibit BACE for Cerebropathy and Dementia Drug Profile1781
  PST-900 Drug Profile1791
  salicylamine Drug Profile1801
  SIN-1502 Drug Profile1811
  Small Molecule for Dementia Drug Profile1821
  Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders Drug Profile1831
  Small Molecule to Activate LPL for CNS and Metabolic Disorders Drug Profile1841
  Small Molecule to Inhibit Glycogene 5 for Dementia Drug Profile1851
  Small Molecules for Frontotemporal Dementia Drug Profile1861
  Small Molecules for Ophthalmology and CNS Disorders Drug Profile1871
  Small Molecules to Agonize HGFR for CNS Disorders Drug Profile1881
  Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia Drug Profile1891
  Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia Drug Profile1901
  SND-14 Drug Profile1911
  SYN-120 Drug Profile1922
  Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders Drug Profile1941
  TAK-070 Drug Profile1951
  TAK-071 Drug Profile1961
  TauC-3 Drug Profile1971
  tolfenamic acid Drug Profile1981
  TPI-287 Drug Profile1994
  TRx-0237 Drug Profile2034
  TTT-3002 Drug Profile2071
  VYTAU-01 Drug Profile2081
  WIB-1001C Drug Profile2091
  zonisamide Drug Profile2102
Dementia Dormant Projects2125
Dementia Discontinued Products2171
Dementia Product Development Milestones21814
  Featured News &Press Releases2181
    Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer s Association International Conference2181
    Jul 22, 2016: TauRx Phase 3 Trial TRx-237-007 in behavioural variant frontotemporal dementia2191
    Jun 28, 2016: Intra-Cellular Therapies Announces Initiation of ITI-007-201 Phase 3 Clinical Trial for the Treatment of Agitation in Patients with Dementia, Including Alzheimer s Disease2191
    Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia2201
    Apr 14, 2016: Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies2211
    Apr 08, 2016: U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia2211
    Feb 25, 2016: Intra-Cellular Therapies Provides Product Update2222
    Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering &Investment Forum2241
    Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia2242
    Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of Nelotanserin For Lewy Body Dementia2261
    Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website2271
    Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression2272
    Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference2291
    Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer s Disease2301
    Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia2302
Appendix2322
  Methodology2321
  Coverage2321
  Secondary Research2321
  Primary Research2321
  Expert Panel Validation2321
  Contact Us2321
  Disclaimer2331

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Dementia - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dementia-Pipeline-Review-H2-2016-2088-16353>
  
APA:
Global Markets Direct - Market Research. (2016). Dementia - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dementia-Pipeline-Review-H2-2016-2088-16353>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.